3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
10
Other hematologic neoplasm
4
Myeloid
2
Dermatologic
2
Genitourinary
1
Conditions
Melanoma
488
Lymphoma, T-Cell, Cutaneous
92
Carcinoma, Non-Small-Cell Lung
89
Mycosis Fungoides
72
Neoplasm Metastasis
71
Skin Neoplasms
62
Neoplasms
61
Sezary Syndrome
60
Carcinoma, Renal Cell
60
Lymphoma, Non-Hodgkin
53
Lymphoma, Large B-Cell, Diffuse
53
Lymphoma
53
Breast Neoplasms
52
Leukemia, Lymphocytic, Chronic, B-Cell
50
Lymphoma, Follicular
47
Lymphoma, Mantle-Cell
46
Lymphoma, B-Cell, Marginal Zone
46
Squamous Cell Carcinoma of Head and Neck
45
Precursor Cell Lymphoblastic Leukemia-Lymphoma
44
Hodgkin Disease
44
Colorectal Neoplasms
43
Burkitt Lymphoma
43
Lymphoma, Large-Cell, Immunoblastic
41
Ovarian Neoplasms
38
Multiple Myeloma
35
Uveal Melanoma
34
Leukemia, Hairy Cell
33
Lymphoma, Large-Cell, Anaplastic
32
Sarcoma
31
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
31
Interventions
cobomarsen
2
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Immune System Diseases
×
Dermatologic
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled